Clinical Evaluation of OFLX in the Treatment of Paranasal Sinusitis.

概要

論文の詳細を見る
The clinical effectiveness, safety and utility of ofloxacin (OFLX) were studied in the treatment of paranasal sinusitis. As a general rule, OFLX was given orally to 89 patients with paranasal sinusitis in daily doses of 600 mg for 5 days to 2 weeks.The clinical effectiveness was evaluated by the doctor in charge as either excellent, effective, slightly effective, ineffective or worse. The clinical efficacy, defined as number of patients evaluated as either excellent or effective, was 83.3% in acute paranasal sinusitis (25/30), 54.8% in chronic paranasal sinusitis (17/31) and 75.0% in acute exacerbation of chronic paranasal sinusitis (21/28). The overall clinical efficacy was 70.8%. The rate of bacteriological elimination was 87.9%. The rate of sensitivity for OFLX in isolated organisms was 85.0% (51/60 strains). Though side effects were observed in 8 patients (9.0%), most of them were mild digestive symptoms. Therefore OFLX is considered to be useful in the treatment of paranasal sinusitis.